Email this article Pre-clinical study of subchronic toxicity of ormustine on rats
- Authors: Chaley V.A.1, Konyaeva O.I.1, Ermakova N.P.1, Merkulova I.B.1, Abramova Т.V.1, Bukhman V.M.1, Kulbachevskaya N.Y.1
-
Affiliations:
- N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
- Issue: Vol 17, No 4 (2018)
- Pages: 98-105
- Section: ORIGINAL REPORTS
- Published: 11.12.2018
- URL: https://bioterapevt.abvpress.ru/jour/article/view/1132
- DOI: https://doi.org/10.17650/1726-9784-2018-17-4-98-105
- ID: 1132
Cite item
Full Text
Abstract
Introduction. In N.N. Blokhin National Medical Research Center of Oncology Ministry of Health of Russia were made preclinical tox icological studies the lyophilized dosage form of ormustine (Ormustine), a new antitumor drug from the class of nitrosoureas. The paper presents some results of study the subchronic toxicity of Ormustine on rats.
Objective. The objective of present study was to investigate the subchronic toxicity of Ormustine on rats with a daily 3 times intravenous administration.
Materials and methods. The study was performed on 40 outbred male rats. Ormustine was administered intravenously daily 3 times in total doses of 300, 200 and 100 mg/kg. The observation period was 45 days. During the observation period, the necessary clinical and laboratory tests were performed. To study the damaging effect of Ormustine to organs and tissues, a pathomorphological examination was carried out at the 3rd and 45th day of observation.
Results. It has been established that Ormustine has hemato-, nephro-, cardio- and gastrointestinal toxicity when administered repeat edly to rats in the three doses studied. The depth and extent of damage, as well as their reversibility, depend on the magnitude of the applied dose of Ormustine.
Conclusion. On the basis of the data obtained, the levels of toxic doses of Ormustin have been determined, namely: a total dose of 300 mg/kg is characterized as a high toxic dose; total doses of 200 and 100 mg/kg are characterized as low toxic doses. This results allows Ormustin to be recommended for next study.Keywords
About the authors
V. A. Chaley
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Author for correspondence.
Email: v.chaley@list.ru
ORCID iD: 0000-0001-7867-2868
24 Kashirskoe Shosse, Moscow 115478 Russian Federation
O. I. Konyaeva
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia24 Kashirskoe Shosse, Moscow 115478 Russian Federation
N. P. Ermakova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia24 Kashirskoe Shosse, Moscow 115478 Russian Federation
I. B. Merkulova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia24 Kashirskoe Shosse, Moscow 115478 Russian Federation
Т. V. Abramova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia24 Kashirskoe Shosse, Moscow 115478 Russian Federation
V. M. Bukhman
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
ORCID iD: 0000-0002-7062-798X
24 Kashirskoe Shosse, Moscow 115478 Russian Federation
N. Yu. Kulbachevskaya
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
ORCID iD: 0000-0003-4214-3475
24 Kashirskoe Shosse, Moscow 115478 Russian Federation
References
Supplementary files
